Rivagelan® contains the active substance rivastigmine.
Rivastigmine belongs to a group of active substances called cholinesterase inhibitors. In patients with Alzheimer’s disease, certain nerve cells in the brain die, resulting in low levels of the neurotransmitter acetylcholine (a substance that enables nerve cells to communicate with each other).
Rivagelan® is used to treat adult patients with mild to moderate Alzheimer’s dementia, a progressive disease of the brain that gradually affects memory, intellectual ability and behaviour.
|Strength||Pack size||Dosage form||Appearance|
|4,6 mg/24 h||7, 30||Transdermal patches|
|9,5 mg/24 h||7, 30||Transdermal patches|